Kymera Therapeutics, Inc. (KYMR) key performance indicators and operating metrics (1 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| KT-621 BroADEN2 Phase 2b Atopic Dermatitis Patients Planned (Approximately) | 200.00 | FY2026-Q1 |
Back to KYMR overview · KYMR earnings · KYMR holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.